What Else Can We Use in The Discrimination of Activated MS Plaques in Addition to Diffusion MRI?
Yıl: 2020 Cilt: 52 Sayı: 1 Sayfa Aralığı: 98 - 99 Metin Dili: İngilizce DOI: 10.5152/eurasianjmed.2020.19238 İndeks Tarihi: 02-07-2020
What Else Can We Use in The Discrimination of Activated MS Plaques in Addition to Diffusion MRI?
Öz: Acute respiratory distress syndrome is characterized by dyspnea at presentation, tachypnea on physicalexamination, findings of bilateral infiltration in chest radiography, refractory hypoxia, and high mortality.Although the main treatment approach is to address the underlying disease, there are also pharmacologicaland nonpharmacological options for supportive treatment. There is currently no pharmacological agent withproven efficacy in this syndrome, and many drugs are being studied for this purpose. One of these is theendothelin receptor antagonist bosentan.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Editöre Mektup Erişim Türü: Erişime Açık
- 1. Unal S, Peker E, Erdogan S, et al. Is It Possible to Discriminate Active MS Lesions with Diffusion Weighted Imaging? Eurasian J Med 2019; 51: 219-23. [CrossRef]
- 2. Telischak NA, Detre JA, Zaharchuk G. Arterial spin labeling MRI: clinical applications in the brain. J Magn Reson Imaging 2015; 41: 1165-80. [CrossRef]
- 3. Evangelou N, Konz D, Esiri MM, et al. Regional axonal loss in the corpus callosum correlates with cerebral white matter lesion volume and distribution in multiple sclerosis. Brain 2000: 123; 1845-49. [CrossRef]
- 4. Filippi M, Rocca MA, De Stefano N, et al. Magnetic resonance techniques in multiple sclerosis: the present and the future. Arch Neurol 2011; 68: 1514-20. [CrossRef]
- 5. Naismith RT, Xu J, Tutlam NT, et al. Increased diffusivity in acute multiple sclerosis lesions predicts risk of black hole. Neurology 2010; 74: 1694- 701. [CrossRef]
- 6. Alper F, Kantarci M, Altunkaynak E, et al. Quantitative magnetic resonance imaging of brainstem volumes, plaques, and surface area in the occipital regions of patients with multiple sclerosis. Acta Radiol 2006; 47: 413-8. [CrossRef]
| APA | KARAMAN A (2020). What Else Can We Use in The Discrimination of Activated MS Plaques in Addition to Diffusion MRI?. , 98 - 99. 10.5152/eurasianjmed.2020.19238 |
| Chicago | KARAMAN Adem What Else Can We Use in The Discrimination of Activated MS Plaques in Addition to Diffusion MRI?. (2020): 98 - 99. 10.5152/eurasianjmed.2020.19238 |
| MLA | KARAMAN Adem What Else Can We Use in The Discrimination of Activated MS Plaques in Addition to Diffusion MRI?. , 2020, ss.98 - 99. 10.5152/eurasianjmed.2020.19238 |
| AMA | KARAMAN A What Else Can We Use in The Discrimination of Activated MS Plaques in Addition to Diffusion MRI?. . 2020; 98 - 99. 10.5152/eurasianjmed.2020.19238 |
| Vancouver | KARAMAN A What Else Can We Use in The Discrimination of Activated MS Plaques in Addition to Diffusion MRI?. . 2020; 98 - 99. 10.5152/eurasianjmed.2020.19238 |
| IEEE | KARAMAN A "What Else Can We Use in The Discrimination of Activated MS Plaques in Addition to Diffusion MRI?." , ss.98 - 99, 2020. 10.5152/eurasianjmed.2020.19238 |
| ISNAD | KARAMAN, Adem. "What Else Can We Use in The Discrimination of Activated MS Plaques in Addition to Diffusion MRI?". (2020), 98-99. https://doi.org/10.5152/eurasianjmed.2020.19238 |
| APA | KARAMAN A (2020). What Else Can We Use in The Discrimination of Activated MS Plaques in Addition to Diffusion MRI?. Eurasian Journal of Medicine, 52(1), 98 - 99. 10.5152/eurasianjmed.2020.19238 |
| Chicago | KARAMAN Adem What Else Can We Use in The Discrimination of Activated MS Plaques in Addition to Diffusion MRI?. Eurasian Journal of Medicine 52, no.1 (2020): 98 - 99. 10.5152/eurasianjmed.2020.19238 |
| MLA | KARAMAN Adem What Else Can We Use in The Discrimination of Activated MS Plaques in Addition to Diffusion MRI?. Eurasian Journal of Medicine, vol.52, no.1, 2020, ss.98 - 99. 10.5152/eurasianjmed.2020.19238 |
| AMA | KARAMAN A What Else Can We Use in The Discrimination of Activated MS Plaques in Addition to Diffusion MRI?. Eurasian Journal of Medicine. 2020; 52(1): 98 - 99. 10.5152/eurasianjmed.2020.19238 |
| Vancouver | KARAMAN A What Else Can We Use in The Discrimination of Activated MS Plaques in Addition to Diffusion MRI?. Eurasian Journal of Medicine. 2020; 52(1): 98 - 99. 10.5152/eurasianjmed.2020.19238 |
| IEEE | KARAMAN A "What Else Can We Use in The Discrimination of Activated MS Plaques in Addition to Diffusion MRI?." Eurasian Journal of Medicine, 52, ss.98 - 99, 2020. 10.5152/eurasianjmed.2020.19238 |
| ISNAD | KARAMAN, Adem. "What Else Can We Use in The Discrimination of Activated MS Plaques in Addition to Diffusion MRI?". Eurasian Journal of Medicine 52/1 (2020), 98-99. https://doi.org/10.5152/eurasianjmed.2020.19238 |
